Cancer Research and Treatment

Kyung Han Nam

2 Articles

Gastrointestinal cancer

Development and Validation of Models to Predict Lymph Node Metastasis in Early Gastric Cancer Using Logistic Regression and Gradient Boosting Machine Methods: Hae Dong Lee, Kyung Han Nam, Cheol Min Shin, Hye Seung Lee, Young Hoon Chang, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sang-Hoon Ahn, Hyung-Ho Kim; Cancer Res Treat. 2023;55(4):1240-1249. Published online March 21, 2023; DOI: https://doi.org/10.4143/crt.2022.1330

Abstract PDF Supplementary Material PubReader ePub

Purpose
To identify important features of lymph node metastasis (LNM) and develop a prediction model for early gastric cancer (EGC) using a gradient boosting machine (GBM) method.
Materials and Methods
The clinicopathologic data of 2556 patients with EGC who underwent gastrectomy were used as training set and the internal validation set (set 1) at a ratio of 8:2. Additionally, 548 patients with EGC who underwent endoscopic submucosal dissection (ESD) as the initial treatment were included in the external validation set (set 2). The GBM model was constructed, and its performance was compared with that of the Japanese guidelines.
Results
LNM was identified in 12.6% (321/2556) of the gastrectomy group (training set & set 1) and 4.3% (24/548) of the ESD group (set 2). In the GBM analysis, the top five features that most affected LNM were lymphovascular invasion, depth, differentiation, size, and location. The accuracy, sensitivity, specificity, and the area under the receiver operating characteristics of set 1 were 0.566, 0.922, 0.516, and 0.867, while those of set 2 were 0.810, 0.958, 0.803, and 0.944, respectively. When the sensitivity of GBM was adjusted to that of Japanese guidelines (beyond the expanded criteria in set 1 [0.922] and eCuraC-2 in set 2 [0.958]), the specificities of GBM in sets 1 and 2 were 0.516 (95% confidence interval, 0.502-0.523) and 0.803 (0.795-0.805), while those of the Japanese guidelines were 0.502 (0.488-0.509) and 0.788 (0.780-0.790), respectively.
Conclusion
The GBM model showed good performance comparable with the eCura system in predicting LNM risk in EGCs.

Citations

Citations to this article as recorded by

Intratumoural and peritumoural CT-based radiomics for diagnosing lepidic-predominant adenocarcinoma in patients with pure ground-glass nodules: a machine learning approach
Y. Zou, Q. Mao, Z. Zhao, X. Zhou, Y. Pan, Z. Zuo, W. Zhang
Clinical Radiology.2024; 79(2): e211. CrossRef
eCura and W-eCura: different scores, different populations, same goal
Rui Morais, Diogo Libanio, João Santos-Antunes
Gut.2024; 73(11): e29. CrossRef
A machine learning model for predicting the lymph node metastasis of early gastric cancer not meeting the endoscopic curability criteria
Minoru Kato, Yoshito Hayashi, Ryotaro Uema, Takashi Kanesaka, Shinjiro Yamaguchi, Akira Maekawa, Takuya Yamada, Masashi Yamamoto, Shinji Kitamura, Takuya Inoue, Shunsuke Yamamoto, Takashi Kizu, Risato Takeda, Hideharu Ogiyama, Katsumi Yamamoto, Kenji Aoi,
Gastric Cancer.2024; 27(5): 1069. CrossRef
The Application of Artificial Intelligence to Cancer Research: A Comprehensive Guide
Amin Zadeh Shirazi, Morteza Tofighi, Alireza Gharavi, Guillermo A. Gomez
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Computed Tomography-Based Radiomics Analysis of Different Machine Learning Approaches for Differentiating Pulmonary Sarcomatoid Carcinoma and Pulmonary Inflammatory Pseudotumor
An-Lin Zhang, Yan-Mei Fu, Zhi-Yang He
Iranian Journal of Radiology.2024;[Epub] CrossRef
Screening of gastric cancer diagnostic biomarkers in the homologous recombination signaling pathway and assessment of their clinical and radiomic correlations
Ahao Wu, Tengcheng Hu, Chao Lai, Qingwen Zeng, Lianghua Luo, Xufeng Shu, Pan Huang, Zhonghao Wang, Zongfeng Feng, Yanyan Zhu, Yi Cao, Zhengrong Li
Cancer Medicine.2024;[Epub] CrossRef

4,905 View
212 Download
6 Web of Science
6 Crossref

p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors: Hee Sung Kim, Hye Seung Lee, Kyung Han Nam, Jiwoon Choi, Woo Ho Kim; Cancer Res Treat. 2014;46(4):383-392. Published online July 17, 2014; DOI: https://doi.org/10.4143/crt.2013.102

Abstract PDF PubReader ePub

Purpose
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous disease group originating from the neuroendocrine cells. Identification of prognostic markers, related to neuroendocrine tissue-selective tumorigenesis, is necessary to find therapeutic targets.
Materials and Methods
A total of 327 patients with GEP-NETs were included in this study; there were 49 gastric, 29 duodenal, 49 pancreatic, 12 hepatobiliary, 33 appendiceal, 5 proximal colon, and 150 distal colon cases. We performed immunostaining with the tissue microarray method for menin, p27, and p18.
Results
We observed negative staining for menin, p27, and p18 in 34%, 21%, and 56% of GEP-NETs, respectively. The loss of p27, but not menin, was positively correlated with the grade of Ki-67. Menin–/p27–, menin–/p27+, menin+/p27–, and menin+/p27+ phenotype groups included 13%, 22%, 8%, and 57% of patients, respectively. A dichotomized comparison showed that menin– or p27– tumors were significantly associated with foregut and midgut localizations, high World Health Organization (WHO) grade, lymph node metastasis, and more advanced stage as compared to menin+/p27+ patients. Kaplan-Meier analysis for the overall survival showed that p27 loss was significantly associated with decreased survival. Multivariate analysis showed that p27 loss is an independent factor for poor overall survival.
Conclusion
Our results revealed that the loss of p27 is associated with poor prognosis and the menin-p27 pathway is important in the tumorigenesis of GEP-NETs.

Citations

Citations to this article as recorded by

Menin in Cancer
Ariana D. Majer, Xianxin Hua, Bryson W. Katona
Genes.2024; 15(9): 1231. CrossRef
Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors
Brittany C. Fields, Reed I. Ayabe, Y. David Seo, Jessica E. Maxwell, Daniel M. Halperin
Current Oncology Reports.2024; 26(11): 1530. CrossRef
Status of Surveillance and Nonsurgical Therapy for Small Nonfunctioning Pancreatic Neuroendocrine Tumors
Dirk-Jan van Beek, Anna Vera D. Verschuur, Lodewijk A.A. Brosens, Gerlof D. Valk, Carolina R.C. Pieterman, Menno R. Vriens
Surgical Oncology Clinics of North America.2023; 32(2): 343. CrossRef
The link between menin and pleiotrophin in the tumor biology of pancreatic neuroendocrine neoplasms
Liping He, Steeve Boulant, Megan Stanifer, Cuncai Guo, Anna Nießen, Mingyi Chen, Klaus Felix, Frank Bergmann, Oliver Strobel, Simon Schimmack
Cancer Science.2022; 113(5): 1575. CrossRef
Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Meng Dai, Christina S Mullins, Lili Lu, Guido Alsfasser, Michael Linnebacher
World Journal of Gastrointestinal Surgery.2022; 14(5): 383. CrossRef
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
Jasminka Hasic Telalovic, Serena Pillozzi, Rachele Fabbri, Alice Laffi, Daniele Lavacchi, Virginia Rossi, Lorenzo Dreoni, Francesca Spada, Nicola Fazio, Amedeo Amedei, Ernesto Iadanza, Lorenzo Antonuzzo
Diagnostics.2021; 11(5): 804. CrossRef
The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung
Mateusz Bilski, Paulina Mertowska, Sebastian Mertowski, Marcin Sawicki, Anna Hymos, Paulina Niedźwiedzka-Rystwej, Ewelina Grywalska
Cancers.2021; 14(1): 177. CrossRef
The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities
Kate Young, Naureen Starling, Anguraj Sadanandam
Seminars in Cancer Biology.2020; 61: 132. CrossRef
Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors
Yuki Yamauchi, Yuzo Kodama, Masahiro Shiokawa, Nobuyuki Kakiuchi, Saiko Marui, Takeshi Kuwada, Yuko Sogabe, Teruko Tomono, Atsushi Mima, Toshihiro Morita, Tomoaki Matsumori, Tatsuki Ueda, Motoyuki Tsuda, Yoshihiro Nishikawa, Katsutoshi Kuriyama, Yojiro Sa
Cancer Research.2020; 80(17): 3620. CrossRef
Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors
Pengchen Chen, Qingshui Wang, Jianwei Xie, Hang Fai Kwok
Seminars in Cancer Biology.2019; 58: 80. CrossRef
Reduced expression of the RNA‐binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27Kip1 levels and poor prognosis
Chongtae Kim, Da Eun Jeong, Sungeun Heo, Eunbyul Ji, Jun Gi Rho, Myeongwoo Jung, Sojin Ahn, Ye‐Jin Kim, Yong‐Sung Kim, Suk Woo Nam, Rohit N Kulkarni, Kyoung Bun Lee, Eun Kyung Lee, Wook Kim
The Journal of Pathology.2018; 246(2): 231. CrossRef
Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors
Yanhong Luo, Hua Zhu, Tao Tan, Jianfeng He
Frontiers in Pharmacology.2018;[Epub] CrossRef
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
E T Aristizabal Prada, C J Auernhammer
Endocrine Connections.2018; 7(1): R1. CrossRef
Deletion ofMen1andsomatostatininduces hypergastrinemia and gastric carcinoids
Sinju Sundaresan, Anthony J Kang, Michael M Hayes, Eun-Young K Choi, Juanita L Merchant
Gut.2017; 66(6): 1012. CrossRef
Cell Cycle Protein Expression in Neuroendocrine Tumors
Yan Shi, Zhi Rong Qian, Sui Zhang, Wanwan Li, Yohei Masugi, Tingting Li, Jennifer A. Chan, Juhong Yang, Annacarolina Da Silva, Mancang Gu, Li Liu, Tsuyoshi Hamada, Keisuke Kosumi, Trevor Dutton, Lauren K. Brais, Reiko Nishihara, Charles S. Fuchs, Shuji Og
Pancreas.2017; 46(10): 1347. CrossRef
DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications
Iris H. Liu, James M. Ford, Pamela L. Kunz
Cancer Treatment Reviews.2016; 44: 1. CrossRef
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases
Michelle Kang Kim, Fei Ye, Daguang Wang, Miao Cui, Stephen C. Ward, Richard R.P. Warner, Sasan Roayaie, Michail Shafir, Myron Schwartz, David Zhang, Steven Itzkowitz
Pancreas.2016; 45(4): 528. CrossRef
Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets
Ellinor Andersson, Yvonne Arvidsson, Christina Swärd, Tobias Hofving, Bo Wängberg, Erik Kristiansson, Ola Nilsson
Modern Pathology.2016; 29(6): 616. CrossRef
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Robert Roskoski
Pharmacological Research.2016; 107: 249. CrossRef
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts
Joo Young Kim, Seung-Mo Hong
Archives of Pathology & Laboratory Medicine.2016; 140(5): 437. CrossRef
Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors
Joakim Crona, Tobias Gustavsson, Olov Norlén, Katarina Edfeldt, Tobias Åkerström, Gunnar Westin, Per Hellman, Peyman Björklund, Peter Stålberg
Annals of Surgical Oncology.2015; 22(S3): 1428. CrossRef
Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
Mark Kidd, Ignat Drozdov, Irvin Modlin
Endocrine-Related Cancer.2015; 22(4): 561. CrossRef

12,280 View
66 Download
26 Web of Science
22 Crossref

Author index